SAXENDA liraglutide (rys) 6mg/mL solution for injection, pre-filled pen Australia - English - Department of Health (Therapeutic Goods Administration)

saxenda liraglutide (rys) 6mg/ml solution for injection, pre-filled pen

novo nordisk pharmaceuticals pty ltd - liraglutide, quantity: 6 mg/ml - injection, solution - excipient ingredients: phenol; hydrochloric acid; water for injections; propylene glycol; dibasic sodium phosphate dihydrate; sodium hydroxide - saxenda is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial body mass index (bmi) of:,- greater than or equal to 30 kg/m2 (obese) or,- greater than or equal to 27 kg/m2 to <30 kg/m2 (overweight) in the presence of at least one weight related comorbidity, such as dysglycaemia (pre-diabetes and type 2 diabetes mellitus), hypertension, dyslipidaemia, or obstructive sleep apnoea.,treatment with saxenda should be discontinued after 12 weeks on the 3.0 mg/day dose if a patient has not lost at least 5% of their initial body weight.

LEVEMIR PENFILL insulin detemir (rys) 100 U/mL injection cartridge Australia - English - Department of Health (Therapeutic Goods Administration)

levemir penfill insulin detemir (rys) 100 u/ml injection cartridge

novo nordisk pharmaceuticals pty ltd - insulin detemir, quantity: 100 u/ml - injection, solution - excipient ingredients: phenol; glycerol; dibasic sodium phosphate dihydrate; metacresol; hydrochloric acid; zinc acetate; water for injections; sodium hydroxide; sodium chloride - treatment of diabetes mellitus. (see 'pharmacology' and 'clinical trials.')

VAGIFEM LOW estradiol 10 ug (as hemihydrate) modified release pessary blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

vagifem low estradiol 10 ug (as hemihydrate) modified release pessary blister pack

novo nordisk pharmaceuticals pty ltd - estradiol hemihydrate, quantity: 10.3 microgram (equivalent: estradiol, qty 10 microgram) - pessary, modified release - excipient ingredients: macrogol 6000; magnesium stearate; lactose monohydrate; hypromellose; maize starch - vagifem low is indicated for the treatment of atrophic vaginitis due to oestrogen deficiency. vagifem low is not intended for children or males.

RYZODEG 70/30 PENFILL 70% insulin degludec (rys) / 30% insulin aspart (rys) 100 U/mL solution for injection cartridge Australia - English - Department of Health (Therapeutic Goods Administration)

ryzodeg 70/30 penfill 70% insulin degludec (rys) / 30% insulin aspart (rys) 100 u/ml solution for injection cartridge

novo nordisk pharmaceuticals pty ltd - insulin aspart, quantity: 180 nmol/ml; insulin degludec, quantity: 420 nmol/ml - injection, solution - excipient ingredients: zinc acetate; phenol; hydrochloric acid; sodium chloride; metacresol; water for injections; sodium hydroxide; glycerol - for use in diabetes mellitus in patients aged 6 years and older.

NovoThirteen European Union - English - EMA (European Medicines Agency)

novothirteen

novo nordisk a/s - catridecacog - blood coagulation disorders, inherited - antihemorrhagics - long-term prophylactic treatment of bleeding in adult and paediatric patients 6 years and above with congenital factor-xiii-a-subunit deficiency.

Medicine administration kit, percutaneous, non-medicated, single-use Australia - English - Department of Health (Therapeutic Goods Administration)

medicine administration kit, percutaneous, non-medicated, single-use

novo nordisk pharmaceuticals pty ltd - 45158 - medicine administration kit, percutaneous, non-medicated, single-use - the kit is intended for the injection of novo nordisk factor products.

Actrapid New Zealand - English - Medsafe (Medicines Safety Authority)

actrapid

novo nordisk pharmaceuticals ltd - neutral insulin, human, pyr 100 iu/ml;   - solution for injection - 100 iu/ml - active: neutral insulin, human, pyr 100 iu/ml   excipient: glycerol hydrochloric acid metacresol sodium hydroxide water for injection zinc - treatment of diabetes mellitus. furthermore indicated for the initial stabilisation of diabetes, during treatment of diabetic ketoacidosis and the hyperosmolar non ketotic syndrome, and during stress situations such as severe infections and major surgery in diabetic patients.

Actrapid Penfill New Zealand - English - Medsafe (Medicines Safety Authority)

actrapid penfill

novo nordisk pharmaceuticals ltd - neutral insulin, human, pyr 100 iu/ml;   - solution for injection - 100 iu/ml - active: neutral insulin, human, pyr 100 iu/ml   excipient: glycerol hydrochloric acid metacresol sodium hydroxide water for injection zinc - treatment of diabetes mellitus. furthermore indicated for the initial stabilisation of diabetes, during treatment of diabetic ketoacidosis and the hyperosmolar non ketotic syndrome, and during stress situations such as severe infections and major surgery in diabetic patients.

Mixtard 30 New Zealand - English - Medsafe (Medicines Safety Authority)

mixtard 30

novo nordisk pharmaceuticals ltd - isophane insulin, human, pyr 70 iu/ml;  ; neutral insulin, human, pyr 30 iu/ml;   - suspension for injection - active: isophane insulin, human, pyr 70 iu/ml   neutral insulin, human, pyr 30 iu/ml   excipient: dibasic sodium phosphate dihydrate glycerol hydrochloric acid metacresol phenol protamine sulfate sodium hydroxide water for injection zinc - treatment of diabetes mellitus.

Penmix 30 Penfill New Zealand - English - Medsafe (Medicines Safety Authority)

penmix 30 penfill

novo nordisk pharmaceuticals ltd - isophane insulin, human, pyr 70 iu/ml;  ; neutral insulin, human, pyr 30 iu/ml;   - suspension for injection - active: isophane insulin, human, pyr 70 iu/ml   neutral insulin, human, pyr 30 iu/ml   excipient: dibasic sodium phosphate dihydrate glycerol hydrochloric acid metacresol phenol protamine sulfate sodium hydroxide water for injection zinc as chloride, approx - treatment of diabetes mellitus.